Schering Corporation

Osi Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Jonathan A Pachter

Ronald J Doll

Yan Wang

Viyyoor Moopil Girijavallabhan

Timothy J Guzi

Anil K Saksena

Yi-Tsung Liu

Leonard G Presta

Mohan Srinivasan

Peter Brams

Denise Leah Williams

Robert Greenberg

Diane Feingersh

Judith Hailey

Alan K Mallams

Kamil Paruch

Jocelyn Rivera

Bernard R Neustadt

David J Blythin

Joel G Berger

Gregory A Reichard

Yaolin Wang

Henry A Vaccaro

Walter Robert Bishop

Bimalendu Dasmahapatra

Leonard Presta

Richard W Bond

Ming Liu

Salam A Shaaban

Elmer J Mirro

Dineshwar Sinha

Michael W Leach

Mark E Cartwright

Mark R Berardi

Lynn Wang

Mark Demma

The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Neutralizing human anti-IGFR antibody

The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

Anti-IGFR1 antibody therapeutic combinations

The present invention provides methods of identifying an agents that inhibit tumor cells from undergoing an epithelial to mesenchymal transition, impair tumor cell mobility, and thus inhibit tumorigenicity. The present invention also provides compositions comprising said agents, and methods for their preparation and use. The present invention also provides methods for inhibiting tumor cells in a patient from undergoing an epithelial to mesenchymal transition by administration of inhibitors of PAK2 kinase, that optionally also inhibit PAK1 kinase. Such methods may be employed in combination with other anti-cancer agents such as EGFR or IGF-1R kinase inhibitors.

Inhibition of EMT induction in tumor cells by anti-cancer agents

The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

Biomarkers for pre-selection of patients for anti-IGF1R therapy

The present invention provides compositions as well as methods for identifying compositions useful for treating or preventing cancer.

p53 modulators

The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention.

In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17&#x3b2;-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17&#x3b2;-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.

17&#x3b2;-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17&#x3b2;-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

17 &#x3b2;-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

There are disclosed compounds of the formula (I):prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17&#x3b2;-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.

Growing community of inventors

Setauket, NY, United States of America

Jonathan A Pachter